End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
60.79
CNY
|
+1.47%
|
|
-1.63%
|
+22.24%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
31,012
|
24,414
|
33,518
|
46,264
|
49,142
|
60,072
|
-
|
-
|
Enterprise Value (EV)
1 |
27,996
|
20,622
|
30,571
|
43,400
|
45,238
|
56,274
|
53,927
|
49,924
|
P/E ratio
|
14.7
x
|
15.3
x
|
16.4
x
|
18.9
x
|
17.1
x
|
17.7
x
|
15.5
x
|
13.8
x
|
Yield
|
1.36%
|
2%
|
2.51%
|
2.14%
|
3.02%
|
3.06%
|
3.29%
|
4.08%
|
Capitalization / Revenue
|
2.11
x
|
1.79
x
|
2.19
x
|
2.56
x
|
1.99
x
|
2.17
x
|
1.93
x
|
1.78
x
|
EV / Revenue
|
1.9
x
|
1.51
x
|
2
x
|
2.4
x
|
1.83
x
|
2.03
x
|
1.73
x
|
1.48
x
|
EV / EBITDA
|
9.67
x
|
8.26
x
|
10.4
x
|
12.5
x
|
10
x
|
11.1
x
|
9.45
x
|
7.92
x
|
EV / FCF
|
19.5
x
|
12.8
x
|
30.4
x
|
21.1
x
|
13.5
x
|
13.7
x
|
13.3
x
|
11
x
|
FCF Yield
|
5.13%
|
7.8%
|
3.29%
|
4.74%
|
7.43%
|
7.32%
|
7.54%
|
9.1%
|
Price to Book
|
2.47
x
|
1.78
x
|
2.19
x
|
2.72
x
|
2.59
x
|
2.84
x
|
2.52
x
|
2.22
x
|
Nbr of stocks (in thousands)
|
978,900
|
978,900
|
978,900
|
988,346
|
988,184
|
988,184
|
-
|
-
|
Reference price
2 |
31.68
|
24.94
|
34.24
|
46.81
|
49.73
|
60.79
|
60.79
|
60.79
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/11/22
|
3/12/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
14,702
|
13,637
|
15,320
|
18,079
|
24,739
|
27,721
|
31,089
|
33,671
|
EBITDA
1 |
2,895
|
2,496
|
2,927
|
3,462
|
4,504
|
5,063
|
5,708
|
6,305
|
EBIT
1 |
2,529
|
2,070
|
2,457
|
2,947
|
3,753
|
4,338
|
5,015
|
5,651
|
Operating Margin
|
17.2%
|
15.18%
|
16.04%
|
16.3%
|
15.17%
|
15.65%
|
16.13%
|
16.78%
|
Earnings before Tax (EBT)
1 |
2,569
|
2,059
|
2,429
|
2,963
|
3,754
|
4,487
|
5,061
|
5,714
|
Net income
1 |
2,112
|
1,597
|
2,047
|
2,449
|
2,853
|
3,380
|
3,846
|
4,331
|
Net margin
|
14.37%
|
11.71%
|
13.36%
|
13.54%
|
11.53%
|
12.19%
|
12.37%
|
12.86%
|
EPS
2 |
2.160
|
1.630
|
2.090
|
2.480
|
2.900
|
3.429
|
3.915
|
4.394
|
Free Cash Flow
1 |
1,437
|
1,609
|
1,004
|
2,057
|
3,361
|
4,120
|
4,064
|
4,544
|
FCF margin
|
9.78%
|
11.8%
|
6.56%
|
11.38%
|
13.59%
|
14.86%
|
13.07%
|
13.5%
|
FCF Conversion (EBITDA)
|
49.64%
|
64.47%
|
34.31%
|
59.41%
|
74.62%
|
81.38%
|
71.19%
|
72.07%
|
FCF Conversion (Net income)
|
68.03%
|
100.73%
|
49.06%
|
83.98%
|
117.81%
|
121.91%
|
105.67%
|
104.91%
|
Dividend per Share
2 |
0.4300
|
0.5000
|
0.8600
|
1.000
|
1.500
|
1.858
|
2.001
|
2.483
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/11/22
|
3/12/23
|
3/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
4,221
|
4,194
|
4,207
|
3,710
|
5,969
|
6,352
|
6,794
|
5,462
|
6,131
|
7,294
|
7,132
|
6,562
|
7,541
|
6,312
|
7,574
|
EBITDA
1 |
558.1
|
1,087
|
802.2
|
853.8
|
-
|
-
|
-
|
-
|
-
|
-
|
1,315
|
1,225
|
750.2
|
1,240
|
1,445
|
EBIT
|
315.8
|
1,023
|
792.6
|
607
|
525.2
|
1,514
|
985.1
|
751.3
|
503.1
|
1,798
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
7.48%
|
24.38%
|
18.84%
|
16.36%
|
8.8%
|
23.83%
|
14.5%
|
13.75%
|
8.21%
|
24.65%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
316.1
|
1,021
|
794.3
|
612.4
|
535.8
|
1,510
|
985.6
|
754.3
|
504.7
|
1,803
|
1,214
|
1,116
|
721.8
|
1,102
|
1,323
|
Net income
1 |
305.7
|
838.7
|
594.4
|
519.3
|
496.5
|
1,151
|
726.1
|
525.5
|
450.3
|
1,364
|
921.7
|
848
|
553.3
|
837.2
|
1,005
|
Net margin
|
7.24%
|
20%
|
14.13%
|
14%
|
8.32%
|
18.12%
|
10.69%
|
9.62%
|
7.35%
|
18.7%
|
12.92%
|
12.92%
|
7.34%
|
13.26%
|
13.26%
|
EPS
2 |
0.3100
|
0.8600
|
0.6000
|
0.5300
|
0.4900
|
1.160
|
0.7500
|
0.5300
|
0.4600
|
1.390
|
0.9164
|
0.6991
|
0.6000
|
1.194
|
1.178
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.938
|
-
|
-
|
-
|
2.201
|
Announcement Date
|
3/11/22
|
4/22/22
|
8/23/22
|
10/28/22
|
3/12/23
|
4/28/23
|
8/29/23
|
10/27/23
|
3/22/24
|
4/19/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3,016
|
3,791
|
2,946
|
2,864
|
3,904
|
3,798
|
6,145
|
10,147
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,437
|
1,609
|
1,004
|
2,057
|
3,361
|
4,120
|
4,064
|
4,544
|
ROE (net income / shareholders' equity)
|
18.1%
|
12.1%
|
14.1%
|
15.2%
|
15.9%
|
16%
|
16.5%
|
16.5%
|
ROA (Net income/ Total Assets)
|
11.1%
|
7.36%
|
8.84%
|
9.48%
|
-
|
8.95%
|
8.67%
|
9.21%
|
Assets
1 |
19,068
|
21,705
|
23,159
|
25,832
|
-
|
37,755
|
44,378
|
47,034
|
Book Value Per Share
2 |
12.80
|
14.00
|
15.60
|
17.20
|
19.20
|
21.40
|
24.20
|
27.30
|
Cash Flow per Share
2 |
2.010
|
2.270
|
1.910
|
3.040
|
4.240
|
5.350
|
4.740
|
6.090
|
Capex
1 |
535
|
615
|
866
|
950
|
831
|
1,881
|
1,219
|
1,359
|
Capex / Sales
|
3.64%
|
4.51%
|
5.65%
|
5.25%
|
3.36%
|
6.78%
|
3.92%
|
4.04%
|
Announcement Date
|
3/19/20
|
3/18/21
|
3/11/22
|
3/12/23
|
3/22/24
|
-
|
-
|
-
|
Last Close Price
60.79
CNY Average target price
71.73
CNY Spread / Average Target +18.00% Consensus |
1st Jan change
|
Capi.
|
---|
| +22.24% | 8.29B | | +38.51% | 727B | | +33.05% | 599B | | -6.23% | 354B | | +18.78% | 328B | | +1.35% | 277B | | +16.00% | 243B | | +8.09% | 205B | | -5.77% | 203B | | +6.19% | 164B |
Other Pharmaceuticals
|